ENSYSCE BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net of -$3.06 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet · last filed 2024-03-15
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2023-12-31 was $0.00.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2023-09-30 was $0.00.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2023-06-30 was $0.00.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2023-03-31 was -$3.06M.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for fiscal 2023 was -$3.06M.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for fiscal 2022 was -$18.93M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | -$3.06M 10-K · filed 2024-03-15 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | -$3.06M 10-Q · filed 2023-11-09 | -$7.85M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$3.06M 10-Q · filed 2023-08-11 | -$7.85M derived: sum of 3 quarters · filed 2023-08-11 | -$10.52M derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | -$3.06M 10-Q · filed 2023-05-15 | -$7.85M derived: sum of 2 quarters · filed 2023-05-15 | -$10.52M derived: sum of 3 quarters · filed 2023-05-15 | |
| 2022-12-31 | -$4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$7.46M derived: sum of 2 quarters · filed 2023-03-30 | -$18.93M 10-K · filed 2023-03-30 | |
| 2022-09-30 | -$2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$14.13M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | -$11.46M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |